/
Oncology
Malignancies
261
Pipeline Programs↗
272
Active Trials↗
218
Companies Involved↗
Malignancies is a highly competitive landscape with 261 programs across 218 companies. The most active players are Institut de Recherches Internationales Servier, Sichuan Baili Pharmaceutical Co., Ltd., AstraZeneca. 28 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical23
Phase 1123
Phase 287
Phase 328
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
183 of 242 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 242 classified programs, each share of the total. Modality classified for 100% of 261 pipeline programs.
Analysis
Trial Status
1,088
clinical trials
Completed471 · 43%
Terminated189 · 17%
Recruiting177 · 16%
Unknown status98 · 9%
Active, not recruiting51 · 5%
Withdrawn47 · 4%
Other55 · 5%
Clinical Trials
Trial Activity
1088 trials
Page 1 of 73
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)